Tomas Babak

This paper identifies potential drug repurposing opportunities through synthetic lethality by analyzing CRISPR screens and drug sensitivity data, but finds pharmacological inhibitors often fail to mimic genetic KO effects.

The paper identifies pharmacogenomic screening principles that predict clinical efficacy in cancer patients with specific driver mutations.

The paper identifies 301 non-coding somatic mutations affecting gene expression in 12 cancer types using TCGA data and shows they have features of noncoding drivers.